Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

Uwe Jacob resigned today from his position as Corporate Development Officer at SuppreMol.

Dr. Uwe Jacob is leaving SuppreMol

Uwe Jacob resigned today from his position as Corporate Development Officer at SuppreMol. Uwe will pursue other activities outside of SuppreMol but he will continue working for the Company as a consultant in specific projects as well as a member of the Scientific Advisory Board. Uwe Jacob is one of the three founders of SuppreMol and contributed considerably to the start-up and early development of the Company since 2002.

About SuppreMol

SuppreMol is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases. The Company is pioneering the development of soluble Fcγ-Receptors (sFcRs), which are recombinant autologous therapeutic proteins with a proven strong immunosuppressive potential. The Company plans to develop sFcRs for the treatment of idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus, rheumatoid arthritis and other autoimmune conditions. The lead product SM101 is presently being tested in Phase I clinical trials.

SuppreMol was founded in 2002 as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. The Company has raised EUR 19.7 million in two financing rounds since May 2006 and received a EUR 1.75 million “Innovative Therapeutics” grant from the BMBF in March 2007.

Contact

Dr Peter Buckel, CEO
SuppreMol GmbH
Am Klopferspitz 19
82152 Martinsried/München
Germany

tel +49-89-30 90 50 68-0
fax +49-89-30 90 50 68-68

info(at)suppremol.com
www.suppremol.com

 

back